


## CDK9-IN-14

<b>Cat. No.:</b>	HY-143585
<b>CAS No.:</b>	2650640-17-6
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>23</sub> F <sub>2</sub> N <sub>3</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	419.42
<b>Target:</b>	CDK
<b>Pathway:</b>	Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	CDK9-IN-14 is a potent and selective CDK9 inhibitor with IC <sub>50</sub> of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	CDK9 6.92 nM (IC <sub>50</sub> )	
<b>In Vitro</b>	CDK9-IN-14 (0-1000 nM) has strong inhibitory effect in MV4;11 cells with IC <sub>50</sub> = 34 nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	CDK9-IN-14 (5 mg/kg; p.o., qd, for 9 days) exhibits significant anti-tumor effect with tumor growth inhibition (TGI) value of 58% <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	Female Nu/Nu mice (6-8 weeks old, 18-22 g, injected with HL-60 cells) <sup>[1]</sup>
	<b>Dosage:</b>	5 mg/kg
	<b>Administration:</b>	p.o., qd, for 9 days
	<b>Result:</b>	Exhibited significant anti-tumor effect with tumor growth inhibition (TGI) value of 58%.

### REFERENCES

[1]. WANG Zhenyu. Compound as cyclin-dependent kinase 9 inhibitor and use thereof. WO2021115335A1

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA